Date: Tuesday 22nd March 2022
Time: 13:30-15:00 GMT | 09:30-11:00 ET
Speakers: Tae Hyun Jung (U.S. Food and Drug Administration), Tim Weaver (Chronic Disease Research Group), Richard Croy (Astellas), David Nimke (Astellas) and Josephine Wolfram (Astellas)
Who is this event intended for? Statisticians or other professionals with an interest in the use of real world data in the regulatory setting.
What is the benefit of attending? To hear first-hand experience of a successful RWE-based submission from different stakeholder perspectives.
You can now register for this event. Registration fees are as follows:
- Members of PSI = Free of charge
- Non-Members of PSI =Free of charge
To register for the session, please click here.
The FDA Real-World Evidence (RWE) Framework was published in Dec. 2018, shedding some light on how Real-World Data (RWD) can be used to support regulatory decision making. This guidance was greatly welcomed in an environment that focuses on efficiency and innovative trial designs. Yet, three years out, there are not many examples of RWE in practice, especially of situations where RWE is the exclusive source of evidence supporting new drug indications. Recently, tacrolimus was approved for Lung transplantation based solely on RWE and we would like to share our experience with statisticians in the pharmaceutical community.
Three stakeholders – the sponsor, RWD vendor and FDA - will share their experiences of the submission and approval process. Topics to be covered include relevant project background & context, identification/selection of RWD, study design & key analysis methods, operational considerations related to study conduct & quality, submission content and labeling.
|
Speakers |
Biographies |
Abstract |
|
|
Rick has been working in clinical development as a statistician in the pharmaceutical industry for over 20 years. For more than 10 of those years, he has been a global statistical lead on various projects, including tacrolimus for transplantation. David is the Real World Evidence-US Lead at Astellas Advanced Informatics and Analytics. His team of observational researchers and analysts conduct research using secondary use databases. Previously, he worked in epidemiology and RWE groups at Astellas, AbbVie, and Abbott Laboratories. David holds a Doctor of Public Health from University of North Carolina. Josie joined the pharmaceutical industry 25 years ago. Following a few years at GSK, she joined Fujisawa in Munich then Astellas in the Netherlands in various statistical roles. She currently leads a small team focused on leveraging real world data to support development projects. |
Richard Croy, David Nimke and Josephine Wolfram will share the background and rationale to pursue this submission, the approach, and key discussion points with the FDA leading up to the submission and during review. Considerations for the choice of RWE and Real-World Data (RWD) used in the pivotal RWD study will be discussed along with the study design elements, key results and challenges. Operational considerations for study conduct and submission will also be addressed |
|
|
Tim Weaver works as a biostatistician in the area of organ transplantation with the Chronic Disease Research Group. In that role he has conducted research using the SRTR database as well as simulation analysis of the organ allocation system. |
Tim Weaver will discuss the source of the RWD, the Scientific Registry of Transplant Recipients database, and the observational nature of the data with its implications for the study design and considerations for analysis. Technical aspects of the data-processing code development, data transfer, and results submission will also be discussed. |
|
|
Tae Hyun Jung, Ph.D., is a Senior Statistical Reviewer in FDA/CDER/OTS/OB/DBVII. He has comprehensive NDA/BLA/PMR review experience from phase III/phase IV safety focused reviews, and phase III efficacy reviews including RWE efficacy. He is also leading multiple RWE/RWD research projects using machine learning/artificial intelligence, evidence synthesis, data quality, and synthetic data. Tae Hyun completed his PhD degree in Biostatistics at Yale University. |
Tae Hyun Jung will share FDA review perspectives and challenges during the review process. Also, the importance of getting quality patient-level data in RWE submission will be addressed. |
Date: Tuesday 22nd March 2022
Time: 13:30-15:00 GMT | 09:30-11:00 ET
Speakers: Tae Hyun Jung (U.S. Food and Drug Administration), Tim Weaver (Chronic Disease Research Group), Richard Croy (Astellas), David Nimke (Astellas) and Josephine Wolfram (Astellas)
Who is this event intended for? Statisticians or other professionals with an interest in the use of real world data in the regulatory setting.
What is the benefit of attending? To hear first-hand experience of a successful RWE-based submission from different stakeholder perspectives.
You can now register for this event. Registration fees are as follows:
- Members of PSI = Free of charge
- Non-Members of PSI =Free of charge
To register for the session, please click here.
The FDA Real-World Evidence (RWE) Framework was published in Dec. 2018, shedding some light on how Real-World Data (RWD) can be used to support regulatory decision making. This guidance was greatly welcomed in an environment that focuses on efficiency and innovative trial designs. Yet, three years out, there are not many examples of RWE in practice, especially of situations where RWE is the exclusive source of evidence supporting new drug indications. Recently, tacrolimus was approved for Lung transplantation based solely on RWE and we would like to share our experience with statisticians in the pharmaceutical community.
Three stakeholders – the sponsor, RWD vendor and FDA - will share their experiences of the submission and approval process. Topics to be covered include relevant project background & context, identification/selection of RWD, study design & key analysis methods, operational considerations related to study conduct & quality, submission content and labeling.
|
Speakers |
Biographies |
Abstract |
|
|
Rick has been working in clinical development as a statistician in the pharmaceutical industry for over 20 years. For more than 10 of those years, he has been a global statistical lead on various projects, including tacrolimus for transplantation. David is the Real World Evidence-US Lead at Astellas Advanced Informatics and Analytics. His team of observational researchers and analysts conduct research using secondary use databases. Previously, he worked in epidemiology and RWE groups at Astellas, AbbVie, and Abbott Laboratories. David holds a Doctor of Public Health from University of North Carolina. Josie joined the pharmaceutical industry 25 years ago. Following a few years at GSK, she joined Fujisawa in Munich then Astellas in the Netherlands in various statistical roles. She currently leads a small team focused on leveraging real world data to support development projects. |
Richard Croy, David Nimke and Josephine Wolfram will share the background and rationale to pursue this submission, the approach, and key discussion points with the FDA leading up to the submission and during review. Considerations for the choice of RWE and Real-World Data (RWD) used in the pivotal RWD study will be discussed along with the study design elements, key results and challenges. Operational considerations for study conduct and submission will also be addressed |
|
|
Tim Weaver works as a biostatistician in the area of organ transplantation with the Chronic Disease Research Group. In that role he has conducted research using the SRTR database as well as simulation analysis of the organ allocation system. |
Tim Weaver will discuss the source of the RWD, the Scientific Registry of Transplant Recipients database, and the observational nature of the data with its implications for the study design and considerations for analysis. Technical aspects of the data-processing code development, data transfer, and results submission will also be discussed. |
|
|
Tae Hyun Jung, Ph.D., is a Senior Statistical Reviewer in FDA/CDER/OTS/OB/DBVII. He has comprehensive NDA/BLA/PMR review experience from phase III/phase IV safety focused reviews, and phase III efficacy reviews including RWE efficacy. He is also leading multiple RWE/RWD research projects using machine learning/artificial intelligence, evidence synthesis, data quality, and synthetic data. Tae Hyun completed his PhD degree in Biostatistics at Yale University. |
Tae Hyun Jung will share FDA review perspectives and challenges during the review process. Also, the importance of getting quality patient-level data in RWE submission will be addressed. |
Date: Tuesday 22nd March 2022
Time: 13:30-15:00 GMT | 09:30-11:00 ET
Speakers: Tae Hyun Jung (U.S. Food and Drug Administration), Tim Weaver (Chronic Disease Research Group), Richard Croy (Astellas), David Nimke (Astellas) and Josephine Wolfram (Astellas)
Who is this event intended for? Statisticians or other professionals with an interest in the use of real world data in the regulatory setting.
What is the benefit of attending? To hear first-hand experience of a successful RWE-based submission from different stakeholder perspectives.
You can now register for this event. Registration fees are as follows:
- Members of PSI = Free of charge
- Non-Members of PSI =Free of charge
To register for the session, please click here.
The FDA Real-World Evidence (RWE) Framework was published in Dec. 2018, shedding some light on how Real-World Data (RWD) can be used to support regulatory decision making. This guidance was greatly welcomed in an environment that focuses on efficiency and innovative trial designs. Yet, three years out, there are not many examples of RWE in practice, especially of situations where RWE is the exclusive source of evidence supporting new drug indications. Recently, tacrolimus was approved for Lung transplantation based solely on RWE and we would like to share our experience with statisticians in the pharmaceutical community.
Three stakeholders – the sponsor, RWD vendor and FDA - will share their experiences of the submission and approval process. Topics to be covered include relevant project background & context, identification/selection of RWD, study design & key analysis methods, operational considerations related to study conduct & quality, submission content and labeling.
|
Speakers |
Biographies |
Abstract |
|
|
Rick has been working in clinical development as a statistician in the pharmaceutical industry for over 20 years. For more than 10 of those years, he has been a global statistical lead on various projects, including tacrolimus for transplantation. David is the Real World Evidence-US Lead at Astellas Advanced Informatics and Analytics. His team of observational researchers and analysts conduct research using secondary use databases. Previously, he worked in epidemiology and RWE groups at Astellas, AbbVie, and Abbott Laboratories. David holds a Doctor of Public Health from University of North Carolina. Josie joined the pharmaceutical industry 25 years ago. Following a few years at GSK, she joined Fujisawa in Munich then Astellas in the Netherlands in various statistical roles. She currently leads a small team focused on leveraging real world data to support development projects. |
Richard Croy, David Nimke and Josephine Wolfram will share the background and rationale to pursue this submission, the approach, and key discussion points with the FDA leading up to the submission and during review. Considerations for the choice of RWE and Real-World Data (RWD) used in the pivotal RWD study will be discussed along with the study design elements, key results and challenges. Operational considerations for study conduct and submission will also be addressed |
|
|
Tim Weaver works as a biostatistician in the area of organ transplantation with the Chronic Disease Research Group. In that role he has conducted research using the SRTR database as well as simulation analysis of the organ allocation system. |
Tim Weaver will discuss the source of the RWD, the Scientific Registry of Transplant Recipients database, and the observational nature of the data with its implications for the study design and considerations for analysis. Technical aspects of the data-processing code development, data transfer, and results submission will also be discussed. |
|
|
Tae Hyun Jung, Ph.D., is a Senior Statistical Reviewer in FDA/CDER/OTS/OB/DBVII. He has comprehensive NDA/BLA/PMR review experience from phase III/phase IV safety focused reviews, and phase III efficacy reviews including RWE efficacy. He is also leading multiple RWE/RWD research projects using machine learning/artificial intelligence, evidence synthesis, data quality, and synthetic data. Tae Hyun completed his PhD degree in Biostatistics at Yale University. |
Tae Hyun Jung will share FDA review perspectives and challenges during the review process. Also, the importance of getting quality patient-level data in RWE submission will be addressed. |
Date: Tuesday 22nd March 2022
Time: 13:30-15:00 GMT | 09:30-11:00 ET
Speakers: Tae Hyun Jung (U.S. Food and Drug Administration), Tim Weaver (Chronic Disease Research Group), Richard Croy (Astellas), David Nimke (Astellas) and Josephine Wolfram (Astellas)
Who is this event intended for? Statisticians or other professionals with an interest in the use of real world data in the regulatory setting.
What is the benefit of attending? To hear first-hand experience of a successful RWE-based submission from different stakeholder perspectives.
You can now register for this event. Registration fees are as follows:
- Members of PSI = Free of charge
- Non-Members of PSI =Free of charge
To register for the session, please click here.
The FDA Real-World Evidence (RWE) Framework was published in Dec. 2018, shedding some light on how Real-World Data (RWD) can be used to support regulatory decision making. This guidance was greatly welcomed in an environment that focuses on efficiency and innovative trial designs. Yet, three years out, there are not many examples of RWE in practice, especially of situations where RWE is the exclusive source of evidence supporting new drug indications. Recently, tacrolimus was approved for Lung transplantation based solely on RWE and we would like to share our experience with statisticians in the pharmaceutical community.
Three stakeholders – the sponsor, RWD vendor and FDA - will share their experiences of the submission and approval process. Topics to be covered include relevant project background & context, identification/selection of RWD, study design & key analysis methods, operational considerations related to study conduct & quality, submission content and labeling.
|
Speakers |
Biographies |
Abstract |
|
|
Rick has been working in clinical development as a statistician in the pharmaceutical industry for over 20 years. For more than 10 of those years, he has been a global statistical lead on various projects, including tacrolimus for transplantation. David is the Real World Evidence-US Lead at Astellas Advanced Informatics and Analytics. His team of observational researchers and analysts conduct research using secondary use databases. Previously, he worked in epidemiology and RWE groups at Astellas, AbbVie, and Abbott Laboratories. David holds a Doctor of Public Health from University of North Carolina. Josie joined the pharmaceutical industry 25 years ago. Following a few years at GSK, she joined Fujisawa in Munich then Astellas in the Netherlands in various statistical roles. She currently leads a small team focused on leveraging real world data to support development projects. |
Richard Croy, David Nimke and Josephine Wolfram will share the background and rationale to pursue this submission, the approach, and key discussion points with the FDA leading up to the submission and during review. Considerations for the choice of RWE and Real-World Data (RWD) used in the pivotal RWD study will be discussed along with the study design elements, key results and challenges. Operational considerations for study conduct and submission will also be addressed |
|
|
Tim Weaver works as a biostatistician in the area of organ transplantation with the Chronic Disease Research Group. In that role he has conducted research using the SRTR database as well as simulation analysis of the organ allocation system. |
Tim Weaver will discuss the source of the RWD, the Scientific Registry of Transplant Recipients database, and the observational nature of the data with its implications for the study design and considerations for analysis. Technical aspects of the data-processing code development, data transfer, and results submission will also be discussed. |
|
|
Tae Hyun Jung, Ph.D., is a Senior Statistical Reviewer in FDA/CDER/OTS/OB/DBVII. He has comprehensive NDA/BLA/PMR review experience from phase III/phase IV safety focused reviews, and phase III efficacy reviews including RWE efficacy. He is also leading multiple RWE/RWD research projects using machine learning/artificial intelligence, evidence synthesis, data quality, and synthetic data. Tae Hyun completed his PhD degree in Biostatistics at Yale University. |
Tae Hyun Jung will share FDA review perspectives and challenges during the review process. Also, the importance of getting quality patient-level data in RWE submission will be addressed. |
Date: Tuesday 22nd March 2022
Time: 13:30-15:00 GMT | 09:30-11:00 ET
Speakers: Tae Hyun Jung (U.S. Food and Drug Administration), Tim Weaver (Chronic Disease Research Group), Richard Croy (Astellas), David Nimke (Astellas) and Josephine Wolfram (Astellas)
Who is this event intended for? Statisticians or other professionals with an interest in the use of real world data in the regulatory setting.
What is the benefit of attending? To hear first-hand experience of a successful RWE-based submission from different stakeholder perspectives.
You can now register for this event. Registration fees are as follows:
- Members of PSI = Free of charge
- Non-Members of PSI =Free of charge
To register for the session, please click here.
The FDA Real-World Evidence (RWE) Framework was published in Dec. 2018, shedding some light on how Real-World Data (RWD) can be used to support regulatory decision making. This guidance was greatly welcomed in an environment that focuses on efficiency and innovative trial designs. Yet, three years out, there are not many examples of RWE in practice, especially of situations where RWE is the exclusive source of evidence supporting new drug indications. Recently, tacrolimus was approved for Lung transplantation based solely on RWE and we would like to share our experience with statisticians in the pharmaceutical community.
Three stakeholders – the sponsor, RWD vendor and FDA - will share their experiences of the submission and approval process. Topics to be covered include relevant project background & context, identification/selection of RWD, study design & key analysis methods, operational considerations related to study conduct & quality, submission content and labeling.
|
Speakers |
Biographies |
Abstract |
|
|
Rick has been working in clinical development as a statistician in the pharmaceutical industry for over 20 years. For more than 10 of those years, he has been a global statistical lead on various projects, including tacrolimus for transplantation. David is the Real World Evidence-US Lead at Astellas Advanced Informatics and Analytics. His team of observational researchers and analysts conduct research using secondary use databases. Previously, he worked in epidemiology and RWE groups at Astellas, AbbVie, and Abbott Laboratories. David holds a Doctor of Public Health from University of North Carolina. Josie joined the pharmaceutical industry 25 years ago. Following a few years at GSK, she joined Fujisawa in Munich then Astellas in the Netherlands in various statistical roles. She currently leads a small team focused on leveraging real world data to support development projects. |
Richard Croy, David Nimke and Josephine Wolfram will share the background and rationale to pursue this submission, the approach, and key discussion points with the FDA leading up to the submission and during review. Considerations for the choice of RWE and Real-World Data (RWD) used in the pivotal RWD study will be discussed along with the study design elements, key results and challenges. Operational considerations for study conduct and submission will also be addressed |
|
|
Tim Weaver works as a biostatistician in the area of organ transplantation with the Chronic Disease Research Group. In that role he has conducted research using the SRTR database as well as simulation analysis of the organ allocation system. |
Tim Weaver will discuss the source of the RWD, the Scientific Registry of Transplant Recipients database, and the observational nature of the data with its implications for the study design and considerations for analysis. Technical aspects of the data-processing code development, data transfer, and results submission will also be discussed. |
|
|
Tae Hyun Jung, Ph.D., is a Senior Statistical Reviewer in FDA/CDER/OTS/OB/DBVII. He has comprehensive NDA/BLA/PMR review experience from phase III/phase IV safety focused reviews, and phase III efficacy reviews including RWE efficacy. He is also leading multiple RWE/RWD research projects using machine learning/artificial intelligence, evidence synthesis, data quality, and synthetic data. Tae Hyun completed his PhD degree in Biostatistics at Yale University. |
Tae Hyun Jung will share FDA review perspectives and challenges during the review process. Also, the importance of getting quality patient-level data in RWE submission will be addressed. |
Date: Tuesday 22nd March 2022
Time: 13:30-15:00 GMT | 09:30-11:00 ET
Speakers: Tae Hyun Jung (U.S. Food and Drug Administration), Tim Weaver (Chronic Disease Research Group), Richard Croy (Astellas), David Nimke (Astellas) and Josephine Wolfram (Astellas)
Who is this event intended for? Statisticians or other professionals with an interest in the use of real world data in the regulatory setting.
What is the benefit of attending? To hear first-hand experience of a successful RWE-based submission from different stakeholder perspectives.
You can now register for this event. Registration fees are as follows:
- Members of PSI = Free of charge
- Non-Members of PSI =Free of charge
To register for the session, please click here.
The FDA Real-World Evidence (RWE) Framework was published in Dec. 2018, shedding some light on how Real-World Data (RWD) can be used to support regulatory decision making. This guidance was greatly welcomed in an environment that focuses on efficiency and innovative trial designs. Yet, three years out, there are not many examples of RWE in practice, especially of situations where RWE is the exclusive source of evidence supporting new drug indications. Recently, tacrolimus was approved for Lung transplantation based solely on RWE and we would like to share our experience with statisticians in the pharmaceutical community.
Three stakeholders – the sponsor, RWD vendor and FDA - will share their experiences of the submission and approval process. Topics to be covered include relevant project background & context, identification/selection of RWD, study design & key analysis methods, operational considerations related to study conduct & quality, submission content and labeling.
|
Speakers |
Biographies |
Abstract |
|
|
Rick has been working in clinical development as a statistician in the pharmaceutical industry for over 20 years. For more than 10 of those years, he has been a global statistical lead on various projects, including tacrolimus for transplantation. David is the Real World Evidence-US Lead at Astellas Advanced Informatics and Analytics. His team of observational researchers and analysts conduct research using secondary use databases. Previously, he worked in epidemiology and RWE groups at Astellas, AbbVie, and Abbott Laboratories. David holds a Doctor of Public Health from University of North Carolina. Josie joined the pharmaceutical industry 25 years ago. Following a few years at GSK, she joined Fujisawa in Munich then Astellas in the Netherlands in various statistical roles. She currently leads a small team focused on leveraging real world data to support development projects. |
Richard Croy, David Nimke and Josephine Wolfram will share the background and rationale to pursue this submission, the approach, and key discussion points with the FDA leading up to the submission and during review. Considerations for the choice of RWE and Real-World Data (RWD) used in the pivotal RWD study will be discussed along with the study design elements, key results and challenges. Operational considerations for study conduct and submission will also be addressed |
|
|
Tim Weaver works as a biostatistician in the area of organ transplantation with the Chronic Disease Research Group. In that role he has conducted research using the SRTR database as well as simulation analysis of the organ allocation system. |
Tim Weaver will discuss the source of the RWD, the Scientific Registry of Transplant Recipients database, and the observational nature of the data with its implications for the study design and considerations for analysis. Technical aspects of the data-processing code development, data transfer, and results submission will also be discussed. |
|
|
Tae Hyun Jung, Ph.D., is a Senior Statistical Reviewer in FDA/CDER/OTS/OB/DBVII. He has comprehensive NDA/BLA/PMR review experience from phase III/phase IV safety focused reviews, and phase III efficacy reviews including RWE efficacy. He is also leading multiple RWE/RWD research projects using machine learning/artificial intelligence, evidence synthesis, data quality, and synthetic data. Tae Hyun completed his PhD degree in Biostatistics at Yale University. |
Tae Hyun Jung will share FDA review perspectives and challenges during the review process. Also, the importance of getting quality patient-level data in RWE submission will be addressed. |
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This is an interactive online training workshop providing an in-depth review of the estimand framework as laid out by ICH E9(R1) addendum with inputs from estimand experts, case studies, quizzes and opportunity for discussions. You will develop an estimand in a therapeutic area of interest to your company. In an online break-out room, you will join a series of team discussions to implement the estimand framework in a case study, aligning estimands, design, conduct, analysis, (assumptions + sensitivity analyses) to the clinical objective and therapeutic setting.
Webinar dedicated to the topic of dissolution of oral solid dosage forms; opportunity to hear from statisticians working in the CMC field, with open question and answers. In addition, the CMC Statistical Network Europe special interest group will discuss advocacy opportunities, have your say to contribute to the future direction.
Initially a brief introduction to AI will be given, followed by a presentation of various applications in medicinal product lifecycle. Several aspects will be discussed including performance, theoretical and practical conditions and also regulatory guidelines.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Who is this event intended for? Statisticians with an interest understanding dose-finding in oncology. What is the benefit of attending? Learn about the state of oncology dose finding, particularly in light of current FDA guidance.
The book club’s usual focus is to read and discuss professional development books. In this short format event you can more easily develop you career without the commitment of reading the whole book - simply listen to the 1-hour long podcast before joining the interactive session on 21 May.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
The Institute of Cancer Research are seeking to appoint a Research Group Leader to join The CRUK Clinical Trials and Statistics Unit at the ICR.
The BioMarin internship programme will enable students to gain valuable experience and knowledge of the processes and systems within BioMarin, whilst gaining an insight into the pharmaceutical/biotech industry.
About cookies on this site
We use cookies to collect and analyse information on site performance and usage, to provide social media features and to enhance and customise content and advertisements.
About cookies on this site
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
CookieHub is a Consent Management Platform (CMP) which allows users to control storage and processing of personal information.
Cloudflare is a global network designed to make everything you connect to the Internet secure, private, fast, and reliable.
Amazon Web Services offers a broad set of global cloud-based products including compute, storage, databases, analytics, networking, mobile, developer tools, management tools, IoT, security, and enterprise applications.
Microsoft Azure is a cloud computing platform offering a wide range of services, including virtual machines, databases, and AI tools.
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic.
Vimeo, Inc. is an American video hosting, sharing, services provider, and broadcaster. Vimeo focuses on the delivery of high-definition video across a range of devices.
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| ARRAffinity | .psiweb.org | Session | |
This cookie is set by websites run on the Windows Azure cloud platform. It is used for load balancing to make sure the visitor page requests are routed to the same server in any browsing session. | |||
| ARRAffinitySameSite | .psiweb.org | Session | |
Used to distribute traffic to the website on several servers in order to optimize response times. | |||
| __cf_bm | .vimeo.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| _cfuvid | .vimeo.com | Session | |
Used by Cloudflare WAF to distinguish individual users who share the same IP address and apply rate limits | |||
| __cf_bm | .glueup.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| AWSALBTGCORS | psi.glueup.com | 7 days | |
AWS Classic Load Balancer Cookie: Load Balancing Cookie: Used to map the session to the instance. Same value as AWSELB. | |||
| PHPSESSID | psi.glueup.com | Session | |
Cookie generated by applications based on the PHP language. This is a general purpose identifier used to maintain user session variables. It is normally a random generated number, how it is used can be specific to the site, but a good example is maintaining a logged-in status for a user between pages. | |||
| History.store | Session | ||
| cookiehub | .psiweb.org | CookieHub | 365 days |
Used by CookieHub to store information about whether visitors have given or declined the use of cookie categories used on the site. | |||
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| vuid | .vimeo.com | 400 days | |
These cookies are used by the Vimeo video player on websites. | |||
| AWSALBCORS | psi.glueup.com | 7 days | |
Amazon Web Services cookie. This cookie enables us to allocate server traffic to make the user experience as smooth as possible. A so-called load balancer is used to determine which server currently has the best availability. The information generated cannot identify you as an individual. | |||
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| _ga_ | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics 4 to determine that two distinct hits belong to the same user across browsing sessions. | |||
| _ga | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics to determine that two distinct hits belong to the same user across browsing sessions. | |||
